Press Releases

The board of directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today, based on the authorisation from the general meeting held on 24 May 2024, resolved on a new issue of shares with pre-emption rights for the Company’s existing shareholders amounting to approximately SEK 56.2 million before issue costs (the “Rights Issue”). The Company has received subscription commitments from existing shareholders, including Linc and MAC Clinical Research, as well as members of the board of directors and management, amounting to approximately SEK 15 million, corresponding to approximately 27 percent of the Rights Issue. The Company has furthermore entered into guarantee undertakings with existing shareholders and external investors which, in aggregate, amount to approximately SEK 33 million, corresponding to approximately 59 percent of the Rights Issue. Consequently, the Rights Issue is covered by subscription commitments and guarantee undertakings amounting to approximately SEK 48 million, corresponding to approximately 86 percent of the Rights Issue.

Initiator Pharma A/S, a clinical-stage biotech company, today announced the expansion of its program in Female Sexual Dysfunction (FSD) to include vulvodynia, a severe chronic pain condition affecting approximately 10% of women worldwide. A Phase 2a clinical proof-of-concept study is expected to start in H2 2025, evaluating pudafensine as a potential treatment for vulvodynia. Funding of the Phase 2a study is secured through a convertible credit agreement with MAC Clinical Research worth up to GBP 2.5 million. The agreement gives MAC Clinical Research the right to convert the credit into Initiator Pharma shares upon the full completion of the planned Phase 2a study at a 40% premium to the TERP in a separately announced rights issue.

The board of directors hereby convene the annual general meeting of Initiator Pharma A/S (the "Company") for Friday, 23 May 2025, at 10:00 AM CEST at the office of DLA Piper Denmark, Oslo…

Initiator Pharma’s Remuneration Report 2024 has now been published and is available on the company ́s home page.

Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting unmet medical needs within the central and peripheral nervous system, today announced that Dr. Göran Ando, former Chairman of Novo Nordisk A/S, is proposed for election to the company’s Board of Directors at the 2025 AGM. Dr. Ando is also appointed as an advisor supporting the Board and management team, effective immediately.